Podcasts about small cell lung cancer

Originally recorded during the 4/28/25 Episode of How Did We Miss That? #157, found here: YouTube: https://www.youtube.com/watch?v=PdNaBvalyzMRumble: https://rumble.com/IndieNewsNetwork/liveOdysee: https://odysee.com/@indienews.network:7/how-did-we-miss-that-ep-157:fBitchute: https://www.bitchute.com/video/4l63bbVF2l4DX: https://x.com/i/broadcasts/1rmxPybNBQbKNAll episode links found at our newsletter: https://www.indiemediatoday.com/p/how-did-we-miss-that-ep-157⭐ No Warrant Raids in Michigan. Guess Why? Protesting Israel.Homes of Pro-Palestine Activists Raided by FBI in Michigan: Kyle Thibodeau and Tristan Taylor, Left Voicehttps://www.leftvoice.org/homes-of-pro-palestine-activist-raided-by-fbi-in-michigan/⭐ This Week's F*ck Israel Segment: Netanyahu's Lies on Iran's Nuclear Bomb Capability, Murdered Palestinian Children, Caitlin JohnstoneThe Wolf Who Cried Bomb: Life and Polityhttps://50317.substack.com/p/a-wolf-who-cried-bomb?r=539iuIn a world of tears, we slowly drown: Aya, Challenge the Narrativehttps://ayauk.substack.com/p/in-a-world-of-tears-we-slowly-drownhttps://substack.com/@caitlinjohnstone/note/c-112111103?utm_source=notes-share-action&r=539iuNobody Say "Fuck Israel, Free Palestine": Caitlin Johnstonehttps://www.caitlinjohnst.one/p/nobody-say-fuck-israel-free-palestine⭐ It's Always Been a CLASS WAR. And the Wealthy Are WinningThe Great South Florida Financial Divide: Indie, Indie Media Todayhttps://www.indiemediatoday.com/p/great-south-florida-financial-divide?r=539iu⭐ A CRAZY story about 2 German girls deported for not having their entire trip planned in advancehttps://x.com/BladeoftheS/status/1914383377290920067https://x.com/PavlovsCat6/status/1914445839272902866Original article in German: https://archive.ph/NRcNR⭐ Lightning Round!What I've Learned in 4 Years of Publishing on Substackhttps://substack.com/@indiemediatoday/note/c-112817900?utm_source=activity_itemChina LEFT THE ROOM (well, not quite, but the charts are really similar to 1987)https://counterpointchina.substack.com/p/the-trump-administration-still-doesnt?r=539iuRussian General Killed by Car Bomb in Moscow Before Talks With US: Kyle Anzalone, Antiwarhttps://news.antiwar.com/2025/04/25/russian-general-killed-by-car-bomb-in-moscow-before-talks-with-us/Fell for it Again Memes - the Sensationhttps://x.com/FellForItAgainAAmazon workers force temporary shutdown after death at JFK8 warehouse: Philip Guelpa, Elliott Murtagh, WSWShttps://www.wsws.org/en/articles/2025/04/14/gcvn-a14.htmlGofundMes: Chanda fighting Small Cell Lung Cancer & AnnaMari fighting Brain Tumorshttps://www.gofundme.com/f/stand-by-chanda-in-her-cancer-fighthttps://www.gofundme.com/f/help-make-annamaris-dreams-come-trueCheck out the 2-hour+ 1-on-1 with 7SEES from 2 weeks ago - we never got a chance to share it herehttps://www.innnewsletter.com/p/connections-conspiracies-and-narrative-inn-1-on-1-7sees-indie-041025-thuI was on Third Rail Podcast this past Friday with The Nature Boyhttps://www.indiemediatoday.com/p/indie-joined-nature-boy-the-third-rail-podcast-042525?r=539iuCheck Out Our BRAND New News Aggregator and Live Streaming Website! https://IndieNewsNow.comCredits:⭐ Co-Host, Producer, Stream & Podcast Engineer, Clip Editor: Indie⭐ Co-Host, Producer & Technical Director: Reef Breland⭐ Thumbnails & Outro: Indie & & Zago Brothers⭐ Intro: BigMadCrab & Jesse Jett⭐ Music: “Redpilled” by Jesse Jett & “Militia Intent” by Jesse JettWherever you are, Indie is!⭐ Social & Video Links: https://linktr.ee/indleft ⭐ Newsletter: https://www.indiemediatoday.com ⭐ How Did We Miss That? Podcast: https://creators.spotify.com/pod/show/independentleftnews/⭐ Indie Media Awards: https://indiemediaawards.substack.com/Reef's Links:⭐ LinkTree: https://linktr.ee/reefbrelandINN Links:⭐ Network Channels: https://indienews.network ⭐ Ko-Fi: https://ko-fi.com/indienewsnetwork⭐ Newsletter: https://www.INNnewsletter.com

Originally recorded during the 4/27/25 Episode of How Did We Miss That? #156, found here: YouTube: https://www.youtube.com/watch?v=wls3dJ5_VMoRumble: https://rumble.com/IndieNewsNetwork/liveOdysee: https://odysee.com/how-did-we-miss-that-ep-156:41c2c637641718da733b4f171806c941559a99b9Bitchute: https://www.bitchute.com/video/0UOB83xlZDd3X: https://x.com/i/broadcasts/1ynKOlkNvgnGR⭐ Remember the California Wildfires? New Problem: Dumping Toxic DebrisThe Government Is Dumping Toxic LA Fire Debris in Local Communities: Carey Wedler, Pleasure to Burnhttps://pleasuretoburn.substack.com/p/the-government-is-dumping-toxic-la?r=539iu⭐ 1700+ Student Visas REVOKED! Rules Being Made Up On the FlyAt Least 1700 Student Visas Have Been Revoked Under Trump So Far: Arturo Dominguez, Decolonized Journalismhttps://extremearturo.substack.com/p/at-least-1700-student-visas-have?r=539iuRecords Restored, status still unknown:https://substack.com/@extremearturo/note/c-112035132?utm_source=notes-share-action&r=539iu⭐ Trump Admin IGNORING Court Orders on DeportationsUS courts fight back against Trump's lawless deportation obsession: Andy Worthingtonhttps://andyworthington.substack.com/p/us-courts-fight-back-against-trumps⭐ Trump Admin Criminalizing Journalism. Journalism IS NOT A CRIME!Trump DOJ Adopts Policy Permitting Journalist Arrests: Kevin Gosztola, The Dissenterhttps://thedissenter.org/trump-doj-policy-permit-journalists-contempt-jail/⭐ Lightning Round!Julian Assange Attends Pope's Funeral with his familyhttps://x.com/wikileaks/status/1916055022233677843https://substack.com/@goldenmonarch/note/c-112392998?utm_source=notes-share-action&r=539iu'Flagrantly Enabling Insider Trading': Trump White House Reportedly Tips Off Wall St on Trade Talks: Jake Johnson, Common Dreamshttps://www.commondreams.org/news/trump-wall-street-trade-talks?utm_source=Common+DreamsTrump Attacks Dem Fundraising Platform ActBlue: Donald Shaw, Sludgehttps://readsludge.com/2025/04/25/trump-attacks-dem-fundraising-platform-actblue/James O'Keefe, Political Operative. Part 1: Polly's Fringe Viewshttps://pollysfringeviews.substack.com/p/james-okeefe-political-operative?r=539iuGofundMes: Chanda fighting Small Cell Lung Cancer & AnnaMari fighting Brain Tumorshttps://www.gofundme.com/f/stand-by-chanda-in-her-cancer-fighthttps://www.gofundme.com/f/help-make-annamaris-dreams-come-trueCatch the 2-hour+ INN 1-on-1 with 7SEES from 2 weeks ago - we never got a chance to share it herehttps://www.innnewsletter.com/p/connections-conspiracies-and-narrative-inn-1-on-1-7sees-indie-041025-thuI was on Third Rail Podcast this past Friday with The Nature Boyhttps://www.indiemediatoday.com/p/indie-joined-nature-boy-the-third-rail-podcast-042525?r=539iuCheck Out Our BRAND New News Aggregator and Live Streaming Website! https://IndieNewsNow.comStay Up to DateAll network activity daily & weekly at https://www.innnewsletter.comClips & more from just me at https://www.IndieMediaToday.comCredits:⭐ Co-Host, Producer, Stream & Podcast Engineer, Clip Editor: Indie⭐ Co-Host, Producer & Technical Director: Reef Breland⭐ Thumbnails & Outro: Indie & & Zago Brothers⭐ Intro: BigMadCrab & Jesse Jett⭐ Music: “Redpilled” by Jesse Jett & “Militia Intent” by Jesse JettWherever you are, Indie is!⭐ Social & Video Links: https://linktr.ee/indleft ⭐ Newsletter: https://www.indiemediatoday.com ⭐ How Did We Miss That? Podcast: https://creators.spotify.com/pod/show/independentleftnews/⭐ Indie Media Awards: https://indiemediaawards.substack.com/Reef's Links:⭐ LinkTree: https://linktr.ee/reefbreland⭐ Twitter: https://twitter.com/ReefBrelandINN Links:⭐ Network Channels: https://indienews.network ⭐ Network Members: https://linktr.ee/innmembers ⭐ Ko-Fi: https://ko-fi.com/indienewsnetwork⭐ Newsletter: https://www.INNnewsletter.com

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3Overview of the structure of antibody-drug conjugates (ADCs)Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLCData from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLCAn overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLCEarly phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093Program faculty:Lauren Byers, MDProfessor and Thoracic Section ChiefDepartment of Thoracic/Head and Neck Medical OncologyMD Anderson Cancer CenterHouston, TexasChristine L. Hann, MD, PhDAssociate Professor of OncologyDirector, Small Cell Lung Cancer TherapeuticsJohns Hopkins University School of MedicineBaltimore, Maryland

Featuring an interview with Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:22) CME information and select publications

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:31) CME information and select publications

Welcome to the Sterile Technique Podcast! It's the podcast about Surgical Technology. Whether you are a CST or CSFA, this podcast helps you earn CE credits and improve your surgery skills in the OR. This episode discusses an article in the March 2025 issue of The Surgical Technologist, the official journal of the Association of Surgical Technologists (AST). The article is titled, "Robot-Assisted Thoracic Surgery in Non-Small Cell Lung Cancer". "Scrub in" at steriletpodcast.com and on Twitter, @SterileTPodcast (twitter.com/SterileTPodcast). This podcast is a Dybas Media production. Sound effects adapted from GarageBand and sindhu.tms at https://freesound.org/people/sindhu.tms/sounds/169065/ and licensed courtesy of https://creativecommons.org/licenses/by-nc/3.0/.

Small cell lung cancer (SCLC) is a smoking-related malignancy that presents at an advanced stage in 70% of patients. Author Anne C. Chiang, MD, PhD, of the Yale University School of Medicine joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the epidemiology, treatment, and prognosis of SCLC. Related Content: Small Cell Lung Cancer

Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like neuroendocrine subtyping, may guide future treatments, while advocacy efforts, such as the Small Cell SMASHERS group @SCLCSMASHERS , offer new support for patients with this historically stigmatized disease.​Misty Dawn Shields MD PhD (Presenter and first author) Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA

Drs. Desai and Abu Rous discuss the  data, as presented at ASCO 2024, and how it may change the field of treatment for limited stage small Adriatic Studycell lung cancer.

Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Disease (2:34) Adjuvant and Neoadjuvant Therapy (22:31) EGFR Exon 20 Insertion Mutations (34:21) Antibody-Drug Conjugates (42:45) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR Mutation-Positive NSCLC, Such as Nonmetastatic Disease, Exon 20 Insertion Mutations and Novel Agents — Helena Yu, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR Mutation-Positive NSCLC — Enriqueta Felip, MD, PhD CME information and select publications

BUFFALO, NY - February 6, 2025 – A new #casereport was #published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report." In this case report, Jenny L. Wu from Vanderbilt University School of Medicine and Wade T. Iams from Vanderbilt-Ingram Cancer Center describe a rare case of drug resistance in a patient with advanced non-small cell lung cancer (NSCLC). The patient, a 42-year-old man who had never smoked, initially responded well to lorlatinib, a targeted therapy designed to treat cancer driven by specific genetic alterations. However, after six months, his cancer began to grow again. Clinicians discovered that this was due to a new genetic change, known as the RUFY1-RET fusion. This finding highlights how cancers can adapt to treatment and the importance of ongoing genetic testing to guide therapy decisions. NSCLC is the most common type of lung cancer, and in some cases, it is driven by genetic changes that can be targeted with specific drugs. The patient's cancer originally had a ROS1 gene rearrangement, which made it responsive to lorlatinib. But as time went on, the cancer started to grow again, and tests revealed a new genetic alteration called RUFY1-RET fusion, which likely caused resistance to lorlatinib. This new genetic change was identified using RNA next-generation sequencing (RNA NGS), an advanced test that can find mutations that standard genetic tests might miss. After discovering the RUFY1-RET gene fusion, the patient was treated with a combination of lorlatinib and pralsetinib, a drug that specifically targets RET gene alterations. While this combination helped control the cancer for about four months, the patient's condition unfortunately worsened after four months. “This is the first reported case of a RET fusion as a potential mechanism of resistance to lorlatinib, it identifies a novel RET fusion partner, and it emphasizes the importance of testing for acquired resistance mutations with both DNA and RNA at the time of progression in patients with targetable oncogenic drivers.” Understanding cases like this can help clinicians and researchers develop more effective treatment strategies, including combination therapies that target multiple genetic changes to combat drug resistance. While the combined therapy in this case provided only temporary benefits, it offers important insights for future research and patient care, particularly for cancers that no longer respond to standard treatments. DOI: https://doi.org/10.18632/oncotarget.28682 Correspondence to: Wade T. Iams, wade.t.iams@vumc.org Keywords: cancer, ROS1 rearrangement, RET rearrangement, non-small cell lung cancer, targeted therapy, case report Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr Enriqueta Felip from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here

Dr Enriqueta Felip from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here

This week's episode will be focusing on additional details for Extensive Stage Small Cell Lung Cancer (SCLC), options for relapsed/refractory disease & advice for trainees. We are so excited to welcome back Dr. Stephen Liu international expert for lung cancer, Director of Thoracic Oncology & Developmental Therapeutics at Georgetown Lombardi Cancer Center and Co-Host of the IASLC Podcast.

This week's episode will be focusing on Small Cell Lung Cancer (SCLC). We will go all the important details on risk factors, diagnostic work-up, staging and treatment of both locoregional and metastatic SCLC. We are so excited to welcome Dr. Stephen Liu international expert for lung cancer, Director of Thoracic Oncology & Developmental Therapeutics at Georgetown Lombardi Cancer Center and Co-Host of the IASLC Podcast.

- Overview of Non-Small Cell Lung Cancer - The Important Role of the Caregiver in Communicating with the Health Care Team - Taking on the Role of the Caregiver - What Research Tells Us about Caregivers - The Caregiver's Role in Decision Making for a Loved One with Non-Small Cell Lung Cancer - Challenges in Communicating with the Health Care Team - Challenges & Rewards of Caregiving - The Increasing Role of Telehealth/Telemedicine Appointments - Coping with Each Day, on Special Occasions & Birthdays - Managing Family & Friends - Long-Distance Caregiving - Self-Care Tips for Managing the Stress of Caregiving - Questions to Ask Our Panel of Experts

- Overview of Non-Small Cell Lung Cancer - The Important Role of the Caregiver in Communicating with the Health Care Team - Taking on the Role of the Caregiver - What Research Tells Us about Caregivers - The Caregiver's Role in Decision Making for a Loved One with Non-Small Cell Lung Cancer - Challenges in Communicating with the Health Care Team - Challenges & Rewards of Caregiving - The Increasing Role of Telehealth/Telemedicine Appointments - Coping with Each Day, on Special Occasions & Birthdays - Managing Family & Friends - Long-Distance Caregiving - Self-Care Tips for Managing the Stress of Caregiving - Questions to Ask Our Panel of Experts

Featuring perspectives from Dr Heather Wakelee, including the following topics: Introduction (0:00) Cases: A man in his late 50s with metastatic carcinoma of the lung, no actionable genomic alteration (AGA), PD-L1-negative, and a man in his early 60s with metastatic squamous cell carcinoma of the lung, PD-L1-negative — Brian P Mulherin, MD and Taral Patel, MD (8:08) Case: A man in his late 60s presenting with metastatic adenocarcinoma of the lung, multiple bone metastases, no AGA; PD-L1 20%; enrolled on ECOG-EA5163 — Priya Rudolph, MD, PhD (21:45) Current and Emerging Immunotherapeutic Strategies for Metastatic Non-Small Cell Lung Cancer (mNSCLC) (30:55) Case: An African American man in his early 60s with 6.2-cm squamous cell carcinoma of right upper lung receives neoadjuvant treatment as per CheckMate 816 — Dr Rudolph (39:16) Case: A man in his late 60s with pT2aN0 invasive adenocarcinoma of the right lower lung, no AGA; PD-L1 5% — Zanetta S Lamar, MD (44:57) Antibody-Drug Conjugates and Other Management Approaches for mNSCLC without AGAs (48:51) Case: A woman in her early 60s diagnosed in 2014 with metastatic adenocarcinoma of the lung treated on ECOG 5508 (carboplatin/paclitaxel/bevacizumab) receives nivolumab on disease progression — Dr Rudolph (56:35) CME information and select publications

Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.

Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPWLE24).

- Non-Small Cell Lung Cancer Overview in the Context of COVID, Seasonal Flu & RSV - Definition of Genomics & Biomarker Testing - The Difference Between Genomics & Genetics - The Role of Biomarker Testing in the Treatment of Non-Small Cell Lung Cancer - Specific Examples of How Biomarker Testing May Inform Treatment Decisions - Precision Medicine & Non-Small Cell Lung Cancer - Current Research in Genomics & Non-Small Cell Lung Cancer - Liquid Biopsies - The Role of the Pathologist - Reviewing Your Biomarker Testing with Your Health Care Team - Key Questions to Ask Your Health Care Team About Biomarker Testing & Its Benefits for Your Treatment Choices - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Care & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

- Non-Small Cell Lung Cancer Overview in the Context of COVID, Seasonal Flu & RSV - Definition of Genomics & Biomarker Testing - The Difference Between Genomics & Genetics - The Role of Biomarker Testing in the Treatment of Non-Small Cell Lung Cancer - Specific Examples of How Biomarker Testing May Inform Treatment Decisions - Precision Medicine & Non-Small Cell Lung Cancer - Current Research in Genomics & Non-Small Cell Lung Cancer - Liquid Biopsies - The Role of the Pathologist - Reviewing Your Biomarker Testing with Your Health Care Team - Key Questions to Ask Your Health Care Team About Biomarker Testing & Its Benefits for Your Treatment Choices - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Care & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

“Precision medicine is an innovative approach to disease prevention and treatment that considers differences in people's genes, injuries, environments, and lifestyles to target the right therapies to the right patients at the right time.” Could a deeper understanding of one of the deadliest lung cancers lead to more effective treatments? Recent research offers a promising way forward, aiming to improve patient outcomes and provide clinicians with valuable insights. Small Cell Lung Cancer (SCLC) is a particularly aggressive form of lung cancer. It spreads fast and does not always respond well to conventional therapies such as chemotherapy. Although SCLC accounts for around 15% of all lung cancer cases, survival rates are extremely low. Only less than 5% of patients live more than five years after diagnosis. These alarming statistics highlight the critical need for new treatments. A team of researchers from the Federal University of Ceará, working together with collaborators from Argentina and Spain, may have found part of the solution. Full blog - https://www.oncotarget.org/2024/12/04/small-cell-lung-cancer-advancing-precision-medicine-with-biomarker-research/ Paper DOI - https://doi.org/10.18632/oncotarget.28660 Correspondence to - Fabio Tavora - fabio.tavora@argospatologia.com Author interview - https://www.youtube.com/watch?v=bJO2MD8AXkY Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28660 Subscribe for free publication alerts from Oncotarget: https://www.oncotarget.com/subscribe/ Keywords - cancer, DLL3, pathology, biomarkers, qupath, small cell carcinoma About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

- Non-Small Cell Lung Cancer Treatment - Current Standard of Care - The Role of Chemotherapy, Radiation Oncology, and Targeted Cancer Therapies - New Treatment Approaches - The Role of Biomarkers and Precision Medicine in Informing Treatment Choices - How Clinical Trials Contribute to Treatment Options - New Ways to Manage Treatment Side Effects, Symptoms, Discomfort, and Pain - Communicating with Your Health Care Team about Quality-of-Life Concerns - Nutrition and Hydration Concerns and Tips - Key Questions to Ask When Communicating with Your Health Care Team - The Increasing Role of Telehealth/Telemedicine Appointments - The Important Role of Lifestyle and Movement - Questions for Our Panel of Experts

- Non-Small Cell Lung Cancer Treatment - Current Standard of Care - The Role of Chemotherapy, Radiation Oncology, and Targeted Cancer Therapies - New Treatment Approaches - The Role of Biomarkers and Precision Medicine in Informing Treatment Choices - How Clinical Trials Contribute to Treatment Options - New Ways to Manage Treatment Side Effects, Symptoms, Discomfort, and Pain - Communicating with Your Health Care Team about Quality-of-Life Concerns - Nutrition and Hydration Concerns and Tips - Key Questions to Ask When Communicating with Your Health Care Team - The Increasing Role of Telehealth/Telemedicine Appointments - The Important Role of Lifestyle and Movement - Questions for Our Panel of Experts

This week's episode will be focusing on Metastatic Non-small Cell Lung Cancer (NSCLC). We are back with Dr. Jennifer Marks, Thoracic Oncologist at the Dana-Farber Cancer Institute. We will go all the important details on the quickly growing and changing systemic therapy options including traditional chemotherapy, immunotherapy and targeted agents 

Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia, and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York, discuss the implications of recent data sets for the current and future management of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostESMO24/Lung).

This week's episode will be focusing on Localized Non-small Cell Lung Cancer (NSCLC). We are very excited to have Dr. Jennifer Marks with us today. Dr. Marks is a thoracic oncologist at the Dana-Farber Cancer Institute, Instructor in Medicine at Harvard Medical School, who also recently took her oncology boards. We will go all the important details on basic of staging, treatment for resectable and unresectable localized NSCLC, and updates in terms of peri-operative and targeted therapies

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/FCS2024).

Educational Objectives • Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer • Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence Moderator:  Lauren Ledbetter, PharmD, BCOP Clinical Pharmacy Specialist, Thoracic Medical Oncology The James Cancer Hospital at The Ohio State University Columbus, Ohio Faculty: Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Clinical Pharmacy Manager University of Kansas  Cancer Center Division of Hematologic Malignancies & Cellular Therapeutics Disclosures Lauren Ledbetter, PharmD, BCOP, has the following financial relationships with commercial interests to disclose: Consultant: The Dedham Group, Charles River Associates Speakers  Bureau: APPOS Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has the following financial relationships with commercial interests to disclose: Consultant: Pfizer, Sanofi, Genmab, Janssen Accreditation: Pharmacy Times Continuing Education™ is accredited by the  Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.5 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit  through October 31, 2025. Supporter: This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.

Featuring perspectives from Dr Jacob Sands, including the following topics: Introduction: A man in his mid 60s with a lung nodule on lung cancer screening (0:00) Current and Future Management of Small Cell Lung Cancer (15:42) CME information and select publications

Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use. Key topics discussed include: •⁠  ⁠The study's primary endpoint of objective response rate and its implications for patient care. •⁠  ⁠The unique mechanism of action of tarlatamab targeting DLL3 and CD3 T cells. •⁠  ⁠The importance of monitoring for side effects such as cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS). •⁠  ⁠Strategies for community oncologists to effectively manage patients receiving this new treatment. Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer. Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care. Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!   Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/WCLC2024/SCLC).

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent approval of Durvalumab in the perioperative settings for non-small cell lung cancer, based on the AEGEAN trial. Join us as we welcome Dr. Sandip Patel, a medical oncologist from UCSD, and Dr. Mara Antonoff, a thoracic surgeon from MD Anderson, to discuss the implications of this new treatment option. We explore the study design of the AEGEAN trial, its differences from other trials like Keynote 671, and the importance of a multidisciplinary approach in managing lung cancer patients. Key topics include: •⁠  ⁠Overview of the AGEAN trial and its findings •⁠  ⁠The significance of neoadjuvant and adjuvant therapies •⁠  ⁠The role of surgical evaluation and molecular profiling •⁠  ⁠Insights on patient selection and treatment strategies As we shift towards more perioperative and postoperative treatments, understanding the nuances of these approaches is crucial for optimizing patient outcomes. Tune in for valuable insights and discussions that can help shape your practice! Don't forget to like, subscribe, and hit the notification bell for more episodes on recent approvals and practice-changing data in oncology! #OncologyBrothers #LungCancer #Dervalumab #AEGEANTrial #MultidisciplinaryCare #MedicalOncology #ThoracicSurgery Website: ⁠http://www.oncbrothers.com/ ⁠ X/Twitter: ⁠https://twitter.com/oncbrothers ⁠ Contact us at info@oncbrothers.com

Featuring perspectives from Dr Edward B Garon and Dr Luis Paz-Ares, including the following topics: Introduction: Ivonescimab (0:00) First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Dr Garon (11:47) Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC — Dr Paz-Ares (42:01) CME information and select publications

Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.

Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/WCLC2024/NontargetedLung).

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics: Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00) NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10) Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations — Dr Dagogo-Jack (34:22) CME information and select publications

Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/WCLC2024/TargetedLung).

Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.

Featuring perspectives from Dr Joshua K Sabari and Dr Helena Yu, including the following topics: Introduction: Checkpoint Inhibitors and Lung Cancer with an EGFR Mutation (0:00) Current Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations — Dr Sabari (5:39) Novel Therapeutic Approaches for NSCLC Harboring EGFR Mutations — Dr Yu (28:21) CME information and select publications

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/WCLC2024/EGFRNSCLC).

Featuring slide presentations and related discussion from Dr Pasi A Jänne, Prof Tom John, Dr Zofia Piotrowska and Dr Alexander I Spira, including the following topics: Recent Advances in the Management of Localized and Locally Advanced Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Prof John (0:00) First-Line Treatment for Advanced NSCLC with an EGFR Mutation — Dr Spira  (32:48) Later-Line Therapy for Advanced NSCLC with an EGFR Mutation — Dr Jänne (1:03:51) Management of NSCLC with an EGFR Exon 20 Mutation — Dr Piotrowska (1:33:33) CME information and select publications

Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation. CME information and select publications here (https://www.researchtopractice.com/EGFRNSCLCThinkTank2024)